Celldex Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1983-01-01
- Employees
- 160
- Market Cap
- $2.5B
- Website
- http://www.celldex.com
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 327
- Registration Number
- NCT01997333
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇮🇹Fondazione Policlinico Universitario A Gemelli, Roma, Lazio, Italy
🇪🇸Hospital Regional Universitario de Malaga - Hospital General, Malaga, Málaga, Spain
Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
- Conditions
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT01791686
- Locations
- 🇺🇸
University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 127
- Registration Number
- NCT01498328
- Locations
- 🇺🇸
University of Southern California (USC) Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Piedmont Atlanta Hospital, Atlanta, Georgia, United States
🇺🇸NorthShore University Health System, Evanston, Illinois, United States
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 745
- Registration Number
- NCT01480479
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
- First Posted Date
- 2011-11-04
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT01465139
- Locations
- 🇺🇸
Rockefeller University, New York, New York, United States
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell LymphomaMarginal Zone B Cell Lymphoma)Any T-cell MalignancySolid Tumors (Metastatic Melanoma, Renal (Clear) Cell CarcinomaHormone-refractory Prostate Adenocarcinoma, Ovarian CancerColorectal Adenocarcinoma, Non-small Cell Lung Cancer)Burkett's LymphomaPrimary Lymphoma of the Central Nervous System
- Interventions
- First Posted Date
- 2011-10-26
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 90
- Registration Number
- NCT01460134
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 120
- Registration Number
- NCT01156753
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
- Conditions
- Interventions
- First Posted Date
- 2010-03-29
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT01094496
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of California - San Diego, La Jolla, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
- Conditions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2016-06-27
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT00948961
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
- Conditions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2010-07-26
- Lead Sponsor
- Celldex Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT00709462
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Carolina BioOncology Institute Cancer, Huntersville, North Carolina, United States